BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1235 related articles for article (PubMed ID: 9356278)

  • 1. Chloroform mode of action: implications for cancer risk assessment.
    Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
    Bogen KT; Gold LS
    Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
    Butterworth BE; Conolly RB; Morgan KT
    Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
    Liao KH; Tan YM; Conolly RB; Borghoff SJ; Gargas ML; Andersen ME; Clewell HJ
    Risk Anal; 2007 Dec; 27(6):1535-51. PubMed ID: 18093051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
    Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
    Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation.
    Tan YM; Butterworth BE; Gargas ML; Conolly RB
    Toxicol Sci; 2003 Sep; 75(1):192-200. PubMed ID: 12805651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.
    Luke NS; Sams R; DeVito MJ; Conolly RB; El-Masri HA
    Toxicol Sci; 2010 May; 115(1):253-66. PubMed ID: 20106946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
    Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice.
    Constan AA; Sprankle CS; Peters JM; Kedderis GL; Everitt JI; Wong BA; Gonzalez FL; Butterworth BE
    Toxicol Appl Pharmacol; 1999 Oct; 160(2):120-6. PubMed ID: 10527910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
    Gaylor DW; Swirsky Gold L
    Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing uncertainty in risk assessment by using specific knowledge to replace default options.
    McClellan RO
    Drug Metab Rev; 1996; 28(1-2):149-79. PubMed ID: 8744594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the carcinogenic activity of diethanolamine and evidence of choline deficiency as a plausible mode of action.
    Leung HW; Kamendulis LM; Stott WT
    Regul Toxicol Pharmacol; 2005 Dec; 43(3):260-71. PubMed ID: 16188361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologically motivated computational modeling of formaldehyde carcinogenicity in the F344 rat.
    Conolly RB; Kimbell JS; Janszen D; Schlosser PM; Kalisak D; Preston J; Miller FJ
    Toxicol Sci; 2003 Oct; 75(2):432-47. PubMed ID: 12857938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chloroform-induced cytolethality in freshly isolated male B6C3F1 mouse and F-344 rat hepatocytes.
    Ammann P; Laethem CL; Kedderis GL
    Toxicol Appl Pharmacol; 1998 Apr; 149(2):217-25. PubMed ID: 9571991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.